Abstract

MLN4924 is an adenosine monophosphate mimic that inhibits the NEDD8 activating enzyme resulting in S-phase defects, DNA damage, and apoptosis. It is currently in phase I clinical trials for the treatment of various cancers. The enantiospecific synthesis depicted is based on a chiral pool strategy that begins with d-ribose.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.